与COVID-19相关的凝血异常:叙述性审查
Massimo Franchini1, Daniele Focosi2, Pier Mannuccio Mannucci3
1Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, Italy.
严重急性呼吸道综合征冠状病毒2 (SARS-COV-2) 可能导致COVID-19相关的凝血病,这是一种既有高凝血和出血并发症的疾病. 本综述总结了关于其机制,特征和管理的当前知识.
科学领域:
- 传染性疾病 传染性疾病
- 血液学 血液学 血液学
- 病理学 病理学 病理学
背景情况:
- 冠状病毒疾病2019 (COVID-19),由SARS-COV-2引起,已经导致全球大流行.
- 中度至重度的COVID-19病例存在系统性凝血病,称为COVID-19相关的凝血病.
- 这种凝血病包括高凝血状态和潜在的出血并发症.
研究的目的:
- 总结有关COVID-19相关凝血病的当前知识.
- 审查潜在的分子机制.
- 描述实验室和临床特征以及管理策略.
主要方法:
- 这是一个叙事评论.
- 进行了关于COVID-19和凝血病的文献搜索.
- 信息进行了综合,以提供全面的概述.
主要成果:
- COVID-19相关的凝血病是一种复杂的疾病,具有双重血栓和出血风险.
- 正在阐明导致凝血病的特定分子途径.
- 临床和实验室发现因患者而异.
结论:
- 了解COVID-19相关的凝血病对于患者管理至关重要.
- 需要进一步的研究,以充分阐明机制和优化治疗.
- 本综述为临床医生和研究人员提供了一个综合资源.
更多相关视频
04:37Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
09:19In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
相关概念视频
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
